ST6GALNAC5: A Potential Drug Target and Biomarker (G81849)

Target Name: ST6GALNAC5

NCBI ID: G81849

ST6GALNAC5

Other Name(s): ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 5, transcript variant 1 | ST6GalNAc V | ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 | Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 (isoform 1) | SIAT7-E | alpha-N-acetylneuraminyl 2,3-betagalactosyl-1,3)-N-acetyl galactosaminide alpha-2,6-sialyltransferase E | sialyltransferase 7 ((alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1,3)-N-acetyl galactosaminide alpha-2,6-sialyltransferase) E | ST6 neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 | SIA7E_HUMAN | Sialyltransferase 7E | Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 | Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase V | Alpha-N-acetylneuraminyl 2,3-betagalactosyl-1,3)-N-acetyl galactosaminide alpha-2,6-sialyltransferase E | alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase V | ST6GALNAC5 variant 1 | sialyltransferase 7E | Sialyltransferase 7 (alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1,3)-N-acetyl galactosaminide alpha-2,6-sialyltransferase) E | ST6 GalNAc alpha-2,6-sialyltransferase 5 | SIAT7E | GD1 alpha synthase | ST6GalNAcV | ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5 | MGC3184 | GalNAc alpha-2,6-sialyltransferase V | Sialyltransferase 7 ((alpha-N-acetylneuraminyl-2,3-beta-galactosyl-1,3)-N-acetyl galactosaminide alpha-2,6-sialyltransferase) E

ST6GALNAC5: A Potential Drug Target and Biomarker

Stem cell biology has revolutionized our understanding of the cellular hierarchy and the role of cell-to-cell interactions in the development and maintenance of tissues and organs. One of the key events in the regulation of stem cell proliferation and differentiation is the transfer of sialic acid from the cell surface to the cell nuclei, which is necessary for the development of tissues and organs. The ST6GALNAC5 gene is a non-coding RNA molecule that is expressed in various tissues and cells, including stem cells, neurons, and glial cells. Its function in the regulation of sialic acid transfer has been studied extensively, and it is now considered as a potential drug target and biomarker.

The ST6GALNAC5 gene

The ST6GALNAC5 gene is a member of the GALNAC family, which includes a variety of enzymes involved in the transfer of sialic acid from the cell surface to the cell nuclei. The ST6GALNAC5 gene was identified using transcriptomics experiments and is located on chromosome 6p21.2.

The function of ST6GALNAC5

Sialic acid is a unique carbohydrate that is present in various tissues and cells of the human body. It is involved in various physiological processes, including cell-to-cell adhesion, migration, and signaling. In particular, sialic acid plays a crucial role in the development and maintenance of tissues and organs, including the nervous system.

ST6GALNAC5 is involved in the transfer of sialic acid from the cell surface to the cell nuclei. It does this by participating in the synthesis and modification of sialic acid on the cell surface. Specifically, it adds an alpha-2,6-sialyl group to sialic acid through a series of enzymatic steps. This process is critical for the development and maintenance of tissues and organs, including the nervous system.

Drug targeting ST6GALNAC5

The potential drug targeting of ST6GALNAC5 is based on its involvement in the transfer of sialic acid from the cell surface to the cell nuclei. This process can be inhibited by drugs that interfere with the activity of ST6GALNAC5. One of the most promising strategies is the use of small molecules that can inhibit the activity of ST6GALNAC5 and prevent the transfer of sialic acid from the cell surface to the cell nuclei.

In addition to the use of small molecules, genetic modification of ST6GALNAC5 has also been considered as a potential strategy for drug targeting. This can be achieved by introducing a genetic modification into ST6GALNAC5, such as a genetic knockdown or an genetic overexpression. The use of genetic modification can be a powerful tool for the manipulation of ST6GALNAC5 function and for the development of new therapeutic strategies.

Biomarker potential

The ST6GALNAC5 gene has also been studied as a potential biomarker for the diagnosis and prognosis of various neurological and psychiatric disorders. The transfer of sialic acid from the cell surface to the cell nuclei is a critical event in the development and maintenance of these tissues, and disruptions in this process can lead to the development of various neurological and psychiatric disorders.

One of the key applications of ST6GALNAC5 as a biomarker is its potential to be used as a diagnostic tool for conditions such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. These conditions are characterized by the progressive loss of neurons and the development of aggregates of beta-amyloid and other neurotransmitters. The transfer of sialic acid from the cell surface to the cell nuclei is believed to play a crucial role in the development and maintenance of these conditions.

In addition to its potential as a diagnostic tool, ST6GALNAC5 has also been studied as a potential therapeutic target for neurodegenerative disorders. The use of small molecules that can inhibit the

Protein Name: ST6 N-acetylgalactosaminide Alpha-2,6-sialyltransferase 5

Functions: Predominantly catalyzes the biosynthesis of ganglioside GD1alpha from GM1b in the brain, by transferring the sialyl group (N-acetyl-alpha-neuraminyl or NeuAc) from CMP-NeuAc to the GalNAc residue on the NeuAc-alpha-2,3-Gal-beta-1,3-GalNAc sequence of GM1b (PubMed:12668675). GD1alpha is a critical molecule in the communication and interaction between neuronal cells and their supportive cells, particularly in brain tissues, and functions as an adhesion molecule in the process of metastasis (By similarity). Also shows activity towards sialyl Lc4Cer (N-acetyl-alpha-neuraminosyl-(2->3)-beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acyl-sphing-4-enine) generating disialyl Lc4Cer, which can lead to the synthesis of disialyl Lewis a (Le(a)), suggested to be a cancer-associated antigen (PubMed:12668675)

The "ST6GALNAC5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ST6GALNAC5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets